These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27548081)

  • 1. Treatment of Non-Alcoholic Fatty Liver Disease.
    Scherer A; Dufour JF
    Dig Dis; 2016; 34 Suppl 1():27-31. PubMed ID: 27548081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P; Bush H; Younossi ZM
    Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of non-alcoholic fatty liver disease.
    Dyson J; Day C
    Dig Dis; 2014; 32(5):597-604. PubMed ID: 25034293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Rotman Y; Sanyal AJ
    Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
    Makri E; Cholongitas E; Tziomalos K
    World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W
    Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current management of non-alcoholic fatty liver disease.
    Lisboa QC; Costa SM; Couto CA
    Rev Assoc Med Bras (1992); 2016 Dec; 62(9):872-878. PubMed ID: 28001263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis and treatment of non-alcoholic fatty liver disease.
    Altinbas A; Sowa JP; Hasenberg T; Canbay A
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
    Oh H; Jun DW; Saeed WK; Nguyen MH
    Clin Mol Hepatol; 2016 Sep; 22(3):327-335. PubMed ID: 27729634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of non-alcoholic fatty liver disease].
    Heebøll S; Vilstrup H; Grønbæk H
    Ugeskr Laeger; 2018 Jul; 180(31):. PubMed ID: 30064623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
    Başaranoğlu M; Örmeci N
    Turk J Gastroenterol; 2014 Apr; 25(2):127-32. PubMed ID: 25003670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
    Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
    Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of NASH fibrosis with pharmacotherapy.
    Alukal JJ; Thuluvath PJ
    Hepatol Int; 2019 Sep; 13(5):534-545. PubMed ID: 31363910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.
    Singh S; Osna NA; Kharbanda KK
    World J Gastroenterol; 2017 Sep; 23(36):6549-6570. PubMed ID: 29085205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.